Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast ...

KYSA-8 is a single-arm registrational Phase 2 trial in which patients with SPS, who had an inadequate response with non-approved treatment options, received a single dose of miv-cel. A total of 26 ...

Biotech investors hunting for explosive growth may want to look closely at two emerging innovators making significant ...

EMERYVILLE, Calif., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...

KYV-101 demonstrated significant efficacy in reducing MG-ADL and QMG scores in gMG patients, with rapid and sustained effects observed post-infusion. The therapy was well tolerated, with no high-grade ...

If you've already heard about FASTag and wondered what Know Your Vehicle (KYV) means, you're not alone. KYV is a new step introduced to make sure your vehicle and your FASTag match up correctly. It's ...

EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...